14 3 3 Proteins — Adapter And Scaffold Proteins is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
14-3-3 proteins are a family of conserved adapter proteins that regulate diverse cellular processes including signal transduction, cell cycle control, and apoptosis. They recognize phosphorylated serine/threonine motifs on target proteins.
Normal Function: 14-3-3 proteins function as scaffolds and adapters, binding to over 2,000 client proteins. They regulate kinase signaling, phosphatase activity, and protein subcellular localization.
Role in Neurodegeneration:
The 14-3-3 proteins are homodimeric or heterodimeric adapter proteins composed of seven isoforms in humans (β, γ, ε, ζ, η, σ, θ). Each monomer (~28 kDa) adopts a gripper-like structure with:
The dimeric structure allows simultaneous binding to two partner proteins, enabling scaffold function.
14-3-3 proteins function as molecular scaffolds and adapter proteins:
The canonical binding motif is RSXpSXP or RXXXpSXP (pS = phosphoserine).
14-3-3 proteins are implicated in neurodegenerative diseases through their roles in apoptosis, protein aggregation, and signaling:
| Disease | Role of 14-3-3 |
|---|---|
| ALS | Cerebrospinal fluid biomarker; sequestered in inclusions |
| PD | Cerebrospinal fluid biomarker; interacts with LRRK2, α-syn |
| AD | Tau phosphorylation modulation; CSF biomarker |
ALS: 14-3-3 proteins are found in cerebrospinal fluid of ALS patients and are detected in spinal cord inclusions. They may contribute to disease through altered signaling in motor neurons.
PD: 14-3-3η and 14-3-3θ interact with LRRK2 and may modulate its kinase activity. 14-3-3 proteins in CSF serve as biomarkers for PD diagnosis.
AD: 14-3-3 proteins modulate tau phosphorylation by affecting kinase/phosphatase activity. They are also potential CSF biomarkers.
| Strategy | Approach | Status |
|---|---|---|
| 14-3-3 modulators | Peptide inhibitors targeting protein-protein interactions | Preclinical |
| Kinase inhibitors | Reduce pathological phosphorylation | Various clinical stages |
| Neuroprotective strategies | Prevent 14-3-3-mediated apoptosis | Research |
Foote M, et al. (2020). 14-3-3 proteins in neurodegeneration. Semin Cell Dev Biol 104: 66-76.
Yashirogi M, et al. (2018). 14-3-3 proteins in Parkinson's disease. J Neurol Neurosurg Psychiatry 89: 391-397.
Shinoda Y, et al. (2019). 14-3-3 proteins as therapeutic targets. Nat Rev Drug Discov 18: 759-775.
The study of 14 3 3 Proteins — Adapter And Scaffold Proteins has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.